T1	MajorClaim 98 194	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
T2	Premise 838 1042	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
T3	Premise 1043 1211	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
T4	Claim 1212 1351	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
R1	Support Arg1:T3 Arg2:T4	
R2	Support Arg1:T2 Arg2:T4	
